SynthesisBMC cancer2026
Adjuvant chemotherapy with or without EGFR-TKIs for resected EGFR-mutated non-small cell lung cancer: a pooled analysis of four randomized controlled trials.
Synthesis in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe role of adding adjuvant epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) to chemotherapy (ETC) among patients with completely resected EGFR-mutated non-small cell lung cancer (NSCLC) remains unclear, particularly with respect to overall survival (OS). A meta-analysis was performed using randomized controlled trials (RCTs), aiming to assess both efficacy and safety profiles of adjuvant chemotherapy plus EGFR-TKIs versus chemotherapy alone.
methodsSix databases were systematically screened to retrieve eligible RCTs evaluating ETC versus placebo plus chemotherapy (PC) as adjuvant therapy. Overall survival (OS) and disease-free survival (DFS) were defined as the primary endpoints, while disease relapse together with treatment-related adverse events (TRAEs) constituted the secondary endpoints.
resultsA total of five RCTs comprising 890 patients were included. Baseline patient characteristics (e.g., age, sex, and disease stage) were comparable between groups. ETC significantly improved OS (HR: 0.56 [0.41, 0.77], P = 0.0003) and DFS (HR: 0.36 [0.23, 0.57], P < 0.0001), with consistent benefits observed across all predefined subgroups. OS rates at 30-60 months and DFS rates at 6-60 months were significantly higher in the ETC group. More tumor recurrences were found in the PC group (RR: 0.37 [0.21, 0.66], P = 0.0007), predominantly due to distant metastases. TRAEs (RR: 1.35 [1.05, 1.73], P = 0.02) and TRAE-related treatment discontinuation or dose reduction (RR: 5.00 [1.12, 22.28], P = 0.03) were more frequent in the ETC group.
conclusionsAdjuvant ETC significantly improves survival and reduces distant recurrence for resected EGFR-mutated NSCLC; however, these benefits should be weighed against a higher but manageable risk of toxicity.
trial registrationPROSPERO ID: CRD420261381478.
Indexed as
Identifiers
42458364What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.